Automated assessment of liver and cardiac toxicities in lead optimisation
This webinar, supported by Tecan, focused on the automated assessment of liver and cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays.
List view / Grid view
Articles
Expert view: Overcoming the problems of working with human primary hepatocytes
Human primary hepatocytes (hpheps) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, and metabolic disease research. However, hpheps don’t survive in standard 2D culture for very long – no longer than two or three days.
Expert view: Biological therapeutics are becoming more popular, here are the reasons
For most people, traditional High-Throughput Screening (HTS) represents large automation rigs and large libraries of small molecules screened against drug targets, however, the development of biological therapeutics has been gaining considerable pace for many reasons.
Drug Target Review: Our 5 Steps to GDPR Compliance
The General Data Protection Regulation (GDPR) is a new set of EU rules governing how a company manages, protects and administers personal data. Whether you are a subscriber, author, advertiser or supplier to our journal, we may hold information about you and we need to keep it private and secure.
The role of biomaterials in stem cell-based regenerative medicine
Despite their vast therapeutic potential in such areas as cell therapy and tissue engineering, stem cells have yet to live up to their original hype and demonstrate widespread clinical success.
Expert view: Reviewing the biggest innovations in antibody screening
The demand for new therapeutics is driving efforts to discover novel antibodies and harness their power in both biologics and adoptive cell therapy areas.
Expert view: How high-content platforms keep pace with the changing face of cell-based drug screening
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
Expert view: Preparing drug discovery for smart screening era
Advances in genomics and structural biology are providing drug discovery scientists with more biological targets to prosecute, and greater information about each one.
Regenerative medicine: enhance cell bioprocessing through cell-based combinatorial culture
Regenerative medicine has emerged as one of the major areas of modern medical therapy. Its primary objective is to restore or establish normal function through the regeneration or replacement of diseased cells, tissues or entire organs. There are a variety of methods and approaches by which this can be achieved.…
Expert view: High-throughput binding kinetic analysis – is it the new frontier in drug discovery?
Sometimes the difference between identifying a partial or super agonist is only the time point at which the binding reaction is measured.
Expert view: Improving R&D productivity with novel screening approaches
The pursuit of improved R&D productivity rates coupled with decreased cycle times has dominated pharmaceutical discourse in recent years.
Expert view: Discovering neuronal cell types
Target the genes that matter for efficient sequencing and analysis with custom-targeted gene panels.
Supporting the progression of phenotypic hits with bioactivity profiling
Bioactivity profiling has been traditionally used to assess the selectivity of new drug candidates in the context of target-based approaches, where pharmacological selectivity is a key requirement.
Screening In-Depth Focus 2018
This In-Depth Focus reviews the history of cancer treatments, looks at improving the translation of disease biology though phenomics, and considers how to enhance cell bioprocessing through cell-based combinatorial culture.
Imaging In-Depth Focus 2018
In this issue the latest applications of molecular imaging in drug development are reviewed by Ben Burke and Steve Archibald and new horizons in 3D microscopy are explored by Dimitri Scholz and Karl Gaff.
